Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Classification of angioedema types using decision tree modeling.

Frontiers in immunology·2026
Same author

Ugeskrift for laeger·2026
Same author

Garadacimab-gxii-A Novel Prophylactic Treatment for Hereditary Angioedema: A Drug Review.

The Annals of pharmacotherapy·2026
Same author

Unsuspected Adverse Drug Reactions to Dermatologic Medications: An Epidemiological Hypothesis-Free Screening Study of Real-World Data in Denmark.

Drug safety·2025
Same author

[Autoimmune progesterone dermatitis].

Ugeskrift for laeger·2025
Same author

Ugeskrift for laeger·2025

Related Experiment Video

Updated: Jan 23, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

8.1K

Hereditary Angio-Oedema for Dermatologists.

Anette Bygum1

  • 1Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark, anette.bygum@hae.dk.

Dermatology (Basel, Switzerland)
|June 6, 2019
PubMed
Summary

Hereditary angio-oedema (HAE) requires specific treatments targeting the kallikrein-kinin pathway, as it does not respond to standard allergy therapies. Early diagnosis and targeted orphan drugs are crucial for managing HAE, reducing complications, and improving patient quality of life.

Keywords:
BradykininHereditary angio-oedemaMutationTreatment

More Related Videos

Analyzing Mitochondrial Transport and Morphology in Human Induced Pluripotent Stem Cell-Derived Neurons in Hereditary Spastic Paraplegia
07:32

Analyzing Mitochondrial Transport and Morphology in Human Induced Pluripotent Stem Cell-Derived Neurons in Hereditary Spastic Paraplegia

Published on: February 9, 2020

8.2K
A Rat Lung Transplantation Model of Warm Ischemia/Reperfusion Injury: Optimizations to Improve Outcomes
07:37

A Rat Lung Transplantation Model of Warm Ischemia/Reperfusion Injury: Optimizations to Improve Outcomes

Published on: October 28, 2021

3.4K

Related Experiment Videos

Last Updated: Jan 23, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
06:33

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis

Published on: June 9, 2018

8.1K
Analyzing Mitochondrial Transport and Morphology in Human Induced Pluripotent Stem Cell-Derived Neurons in Hereditary Spastic Paraplegia
07:32

Analyzing Mitochondrial Transport and Morphology in Human Induced Pluripotent Stem Cell-Derived Neurons in Hereditary Spastic Paraplegia

Published on: February 9, 2020

8.2K
A Rat Lung Transplantation Model of Warm Ischemia/Reperfusion Injury: Optimizations to Improve Outcomes
07:37

A Rat Lung Transplantation Model of Warm Ischemia/Reperfusion Injury: Optimizations to Improve Outcomes

Published on: October 28, 2021

3.4K

Area of Science:

  • Immunology
  • Genetics
  • Rare Diseases

Background:

  • Hereditary angio-oedema (HAE) is a rare genetic disorder characterized by recurrent swelling episodes.
  • HAE can manifest with severe abdominal pain and life-threatening upper airway obstruction.
  • Traditional anti-allergic treatments are ineffective for HAE, necessitating targeted therapies.

Purpose of the Study:

  • To highlight the importance of recognizing and diagnosing HAE.
  • To emphasize the need for specific treatments targeting the kallikrein-kinin pathway.
  • To underscore the benefits of early diagnosis and appropriate therapy for HAE patients.

Main Methods:

  • Review of clinical features and diagnostic criteria for HAE.
  • Discussion of genetic underpinnings, including SERPING1, F12, ANGPT1, and PLG mutations.
  • Overview of current and emerging therapeutic strategies for HAE.

Main Results:

  • HAE diagnosis is often delayed due to lack of awareness, increasing patient risks.
  • Specific therapies targeting the kallikrein-kinin pathway are effective for HAE.
  • New treatments have become available, with more in development.

Conclusions:

  • Prompt diagnosis of HAE is critical to prevent severe complications and mortality.
  • Targeted orphan drug therapies significantly improve HAE management and quality of life.
  • Increased awareness and timely intervention are essential for optimal HAE patient outcomes.